Stock Research for GCVRZ

GCVRZ

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

GCVRZ Stock Chart & Research Data

The GCVRZ chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GCVRZ chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


GCVRZ Due diligence Resources & Stock Charts

The GCVRZ stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GCVRZ Detailed Price Forecast - CNN Money CNN View GCVRZ Detailed Summary - Google Finance
Yahoo View GCVRZ Detailed Summary - Yahoo! Finance Zacks View GCVRZ Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View GCVRZ Trends & Analysis - Trade-Ideas Barrons View GCVRZ Major Holders - Barrons
NASDAQ View GCVRZ Call Transcripts - NASDAQ Seeking View GCVRZ Breaking News & Analysis - Seeking Alpha
Spotlight View GCVRZ Annual Report - CompanySpotlight.com OTC Report View GCVRZ OTC Short Report - OTCShortReport.com
TradeKing View GCVRZ Fundamentals - TradeKing Charts View GCVRZ SEC Filings - Bar Chart
WSJ View Historical Prices for GCVRZ - The WSJ Morningstar View Performance/Total Return for GCVRZ - Morningstar
MarketWatch View the Analyst Estimates for GCVRZ - MarketWatch CNBC View the Earnings History for GCVRZ - CNBC
StockMarketWatch View the GCVRZ Earnings - StockMarketWatch MacroAxis View GCVRZ Buy or Sell Recommendations - MacroAxis
Bullish View the GCVRZ Bullish Patterns - American Bulls Short Pains View GCVRZ Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View GCVRZ Stock Mentions - StockTwits PennyStocks View GCVRZ Stock Mentions - PennyStockTweets
Twitter View GCVRZ Stock Mentions - Twitter Invest Hub View GCVRZ Investment Forum News - Investor Hub
Yahoo View GCVRZ Stock Mentions - Yahoo! Message Board Seeking Alpha View GCVRZ Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for GCVRZ - SECform4.com Insider Cow View Insider Transactions for GCVRZ - Insider Cow
CNBC View GCVRZ Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GCVRZ - OTC Markets
Yahoo View Insider Transactions for GCVRZ - Yahoo! Finance NASDAQ View Institutional Holdings for GCVRZ - NASDAQ


Stock Charts

FinViz View GCVRZ Stock Insight & Charts - FinViz.com StockCharts View GCVRZ Investment Charts - StockCharts.com
BarChart View GCVRZ Stock Overview & Charts - BarChart Trading View View GCVRZ User Generated Charts - Trading View




Latest Financial News for GCVRZ


Meet the biotech shooting to be Bay Area's 10th life sciences IPO this year
Posted on Monday August 20, 2018

The 10-year-old company made a big splash last year with a potential multiple sclerosis drug deal with Sanofi. But it also has programs targeting inflammatory skin conditions and cancer.


Bay Area's 10th life science IPO this year raises $26M as No. 11 hopes to fetch $86M
Posted on Monday August 20, 2018

The life sciences sector has produced more than half of the Bay Area's new public companies this year.


Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018
Posted on Tuesday August 14, 2018

GlaxoSmithKline’s (GSK) Vaccines segment includes its influenza, meningitis, shingles, and established vaccines. The segment’s revenue grew 13% YoY (year-over-year) to ~1.3 billion British pounds in Q2 2018, as a result of 16% operating revenue growth and a 3% impact by foreign exchange. The chart below shows the segment’s revenue since the first quarter of 2017.


Novo Nordisk’s Fast-Acting Insulins: A Performance Overview
Posted on Tuesday August 14, 2018

In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.